A Comparative Pharmacokinetic Study of CM326 in Healthy Subjects

A Randomized, Open-Label, Parallel-Controlled Phase I Study to Compare the Pharmacokinetics, Safety, and Immunogenicity of a Single Subcutaneous Injection of CM326 Via Different Delivery Devices in Healthy Subjects

This is a randomized, open-label, parallel-controlled study to compare the PK, safety, and immunogenicity of CM326 administered via different delivery devices in healthy subjects.

Study Overview

• Status: Not yet recruiting
• Conditions: Healthy Subjects
• Intervention / Treatment: Drug: CM326(formulation 1); Drug: CM326(formulation 2)

• Study Type: Interventional
• Enrollment (Estimated): 192
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Clinical Trials Information Group officer; Phone Number: +86-0311-69085587; Email: ctr-contact@cspc.cn
• Study Contact Backup: Name: Wei Hu; Phone Number: +86-13856086475; Email: huwei@ahmu.edu.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Participants [c1.1]must be informed of the study before it begins, fully understand the study content, procedures, and potential adverse reactions, and voluntarily sign the written ICF;
2. Healthy male participants aged 18 to 55 years;
3. Body weight between 55.0 and 85.0 kg, and body mass index between 19.0 and 26.0 kg/m²;
4. Physical examination, vital signs, 12-lead electrocardiogram, laboratory tests, and other examination results are normal, or abnormal but without clinical significance;
5. Participants and their partners agree to use effective and reliable contraceptive methods from signing the ICF until 3 months after dosing;
6. Participants are able to communicate well with the investigator, and to understand and comply with the requirements of the study.

Exclusion Criteria:

1. History of chronic diseases or severe diseases involving the circulatory system, blood or hematopoietic system, respiratory system, endocrine system, urinary system, digestive system, immune system, psychiatric or nervous system, reproductive system, etc.;
2. Presence or suspicion of any active viral, bacterial, fungal, or parasitic infection within 14 days before dosing;
3. Participants who have undergone major surgery within 3 months before screening, or who plan to undergo major surgery during the study period;
4. History of allergies to drugs, food, etc., or Participants who may be allergic to the study drug or its components in the Investigator's judgment;
5. Positive result for any of the following: hepatitis B surface antigen, hepatitis C antibody, Treponema pallidum antibody, human immunodeficiency virus antigen/antibody;
6. History of drug abuse, or use of illicit drugs within 3 months before screening, or habitual use of any psychotropic drugs (including herbal medicines), or a positive urine drug screen;
7. Blood loss or blood donation of more than 200 mL within 3 months before screening;
8. Intolerance to subcutaneous injection, or presence of abdominal scars that affect subcutaneous administration, and any skin abnormalities and/or tattoos that may affect the safety assessment of the injection site;
9. Use of any prescription drugs, over-the-counter drugs, herbal medicines or vitamin and dietary supplements within 14 days or 5 half-lives (whichever is longer) before dosing;
10. Use of any marketed or investigational biological products within 6 months or 5 half-lives (whichever is longer) before dosing;
11. Participants who have previously used CM326 or drugs targeting TSLP;
12. Vaccination within 4 weeks before screening, or plan to receive such vaccines during the study;
13. Participation in any clinical trial within 3 months before screening;
14. Average daily smoking of more than 5 cigarettes within 3 months before screening, or unwilling to avoid using any tobacco products during the study;
15. Regular alcohol consumption within 3 months before screening, defined as weekly alcohol consumption exceeding 14 units (1 unit = 360 mL of 5% alcohol beer or 45 mL of 40% alcohol spirits or 150 mL of 12% alcohol wine), or inability to stop alcohol intake during the study, or a positive blood alcohol test;
16. Regular consumption of excessive amounts of tea, coffee, and/or caffeinated beverages within 3 months before screening;
17. Participants who have special dietary requirements and are unable to comply with the standardized diet;
18. History of needle phobia or hemophobia, or d difficulty with venipuncture or unable to tolerate venous puncture;
19. Participants who, in the Investigator's judgment, may be unable to complete the study for other reasons or are considered unsuitable for enrollment.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: CM326 group 1; Subjects will receive a single subcutaneous injection of CM326 on Day 1.	Drug: CM326(formulation 1); subcutaneous injection
Experimental: CM326 group 2; Subjects will receive a single subcutaneous injection of CM326 on Day 1.	Drug: CM326(formulation 2); subcutaneous injection

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum concentration (Cmax)	To compare the Cmax of CM326 administered via different delivery devices	Pre-dose at day 1 to Day 113
Area under the concentration-time curve from zero to infinity (AUCinf)	To compare the AUCinf of CM326 administered via different delivery devices	Pre-dose at day 1 to Day 113

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time to maximum concentration (Tmax)	To characterize the Tmax of CM326 in healthy subjects	Pre-dose at day 1 to Day 113
Area under the concentration-curve from zero to the last quantifiable concentration (AUClast)	To characterize the AUClast of CM326 in healthy subjects	Pre-dose at day 1 to Day 113
Terminal elimination half-life (t1/2)	To characterize the t1/2 of CM326 in healthy subjects	Pre-dose at day 1 to Day 113
Apparent clearance (CL/F)	To characterize the Vz/F of CM326 in healthy subjects	Pre-dose at day 1 to Day 113
Apparent volume of distribution (Vz/F)	To characterize the Vz/F of CM326 in healthy subjects	Pre-dose at day 1 to Day 113
Number of subjects with adverse events as Assessed by CTCAE v6.0	To assess the safety of CM326 in healthy subjects	Pre-dose at day 1 to Day 113
Incidence of ADA	To assess the immunogenicity of CM326 in healthy subjects	Pre-dose at day 1 to Day 113

Collaborators and Investigators

• Sponsor: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Estimated): April 20, 2026
• Primary Completion (Estimated): October 1, 2026
• Study Completion (Estimated): December 31, 2026

Study Registration Dates

• First Submitted: April 14, 2026
• First Submitted That Met QC Criteria: April 23, 2026
• First Posted (Actual): April 30, 2026

Study Record Updates

• Last Update Posted (Actual): April 30, 2026
• Last Update Submitted That Met QC Criteria: April 23, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Other Study ID Numbers: CM326-006

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No